Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

tigator, Thomas J. Louie, M.D., presented top-line data from Optimer's fidaxomicin North American Phase 3 clinical study for patients with Clostridium difficile infection at the European Congress of Clinical Microbiology and Infectious Diseases meeting, which showed the trial met its primary endpoint of achieving clinical cure compared to Vancocin(R). In addition, the top-line data showed that patients treated with fidaxomicin experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a higher global cure (cure with no recurrence within four weeks) compared to Vancocin (p=0.006).
  • Clinical investigator, Mark A. Miller, M.D., presented additional data from Optimer's fidaxomicin North American Phase 3 clinical study at the Digestive Disease Week 2009 Conference focusing on patient risk factors believed to be predictive of CDI recurrence following treatment. These risk factors include albumin levels, white blood cell (WBC) count and temperature and strain types of CDI. The data showed that fidaxomicin overall demonstrated a lower recurrence rate compared to Vancocin (p=0.004) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains.
  • The United States Patent and Trademark Office issued Optimer a production patent covering steps used in the manufacture of fidaxomicin.
  • About Optimer Pharmaceuticals

    Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed t
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
    6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
    7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
    8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
    9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
    10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
    11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
    (Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader ... company overview at the Nomura Biotechnology Conference on Thursday, November ... MA. A live webcast of the ... of the Company,s website, www.isispharm.com .  A replay will ... will be archived for a limited time. About ...
    (Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
    (Date:10/27/2014)... and TORONTO , Oct. 27, ... ) (OTCQB: GNBT) today announced two presentations demonstrating ... by its novel proprietary cancer immunotherapeutic AE37 vaccine ... cancer patients. The AE37 cancer vaccine is being ... Inc. ( www.antigenexpress.com ). The presentations are being ...
    Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
    ... and GERMANTOWN, Maryland, May 3, 2012 ... assay to detect rupture of fetal membranes (ROM)   - ... Novel FDA-cleared test is highly synergistic with ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today announced ...
    ... ANGELES, May 3, 2012 MD+DI ( ... brand providing the medical device industry with the latest news ... for Best Cover in the Medical, Dental & Related ... May 2011 cover was also a finalist for the ...
    ... Corporation (Nasdaq: VRNM ), a leading industrial biotechnology ... today announced that it will release 2012 first ... close. In conjunction with the release, the Company will host ... at 5:00 p.m. ET. The call may be ...
    Cached Biology Technology:QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 2QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 3QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 4QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 5MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category 2Verenium Corporation To Announce First Quarter 2012 Financial Results 2
    (Date:10/29/2014)... Researching the safety of nanoparticles is all the rage. ... topic, examining the question of whether titanium dioxide nanoparticles ... into the body, whether carbon nanotubes from electronic products ... to be or whether nanoparticles in food can get ... Public interest is great, research funds are flowing – ...
    (Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
    (Date:10/29/2014)... new study on a large cohort of kidney cancer ... of the disease -- and reveals an apparent link ... cancer, particularly in Romania. , The research, by an ... and Genome Quebec Innovation Centre in Montreal, underscores the ... acid. The compound, found in plants of the Aristolochia ...
    Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3
    ... Virology group at the Institute for Molecular Medicine Finland ... national and international collaborators, developed a new cell screening ... drugs. The researchers were able to identify two novel ... the efficacy of a previously known drug saliphenylhalamide. ...
    ... to discontinue in 2013 a unique environmental research project that ... topics for almost 40 years would be a "huge loss ... humanity." That,s the focus of a viewpoint article in ACS, ... Hering, D. L. Swackhamer and W. H. Schlesinger explain that ...
    ... on the Florida campus of The Scripps Research Institute have ... for one of the diseases closely linked to fragile X ... memory impairment, and is the only known single-gene cause of ... the journal ACS Chemical Biology September 4, 2012, ...
    Cached Biology News:Harnessing anticancer drugs for the future fight against influenza 2Scripps Florida scientists design molecule that reverses some fragile X syndrome defects 2
    ... Forma's stainless steel rack ... adjustable mechanism that permits ... shaking angles, and "snap-in" ... universal rack holder will ...
    ... Source: Escherichia coli RY 13 5'G AATTC3' 3'CTTAA ... 15 min or ethanol precipitation. Storage Conditions: 10mM ... DTT, 0.15% Triton X-100, 0.01% BSA, 50% glycerol. ... at -20C. Unit Definition: One unit is defined ...
    ... shaker flask clips, purpose-designed to firmly retain ... clips are equipped with a top retainer ... a bottom retainer spring, and silicon tubing ... glassware. Clips include the required mounting ...
    ANTI DIPHTH TOX A SU...
    Biology Products: